SectoralDirect and Regular plans, Growth and IDCW options
Data as on 30-10-2026
Invesco India Pharma and Healthcare Fund is a Sectoral fund run by Invesco Mutual Fund. On 30-09-2026, it managed ₹436 Cr of investors' money.
NAV on 30-10-2026: Direct Plan Growth ₹9.66 (up 1.05% that day); Regular Plan Growth ₹9.63 (up 0.94% that day).
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Period | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| This fund (Direct) | +0.73% | -- | -- | -- | -- | -- | -- |
| This fund (Regular) | +0.52% | -- | -- | -- | -- | -- | -- |
| BSE Healthcare TRI | +0.24% | −0.99% | +12.80% | +12.37% | +23.01% | +15.61% | +12.48% |
| Sectoral average | −1.70% | -- | -- | -- | -- | -- | -- |
| Best in Sectoral | +7.03% | -- | -- | -- | -- | -- | -- |
| Worst in Sectoral | −7.36% | -- | -- | -- | -- | -- | -- |
| Rank in Sectoral | 4/20 | -- | -- | -- | -- | -- | -- |
Category rows compare the Direct plans of 20 Sectoral funds. Rank 1 is the highest return.
The five Sectoral funds with the best three year return, and this fund. Direct plans.
| Fund name | Rank | AUM (Cr) | Exp. ratio | 1Y return | 3Y return | 3Y alpha | 3Y beta | 3Y Sharpe | 3Y Sortino | |
|---|---|---|---|---|---|---|---|---|---|---|
| DSP Healthcare Fund | 1/9 | 3,750 | 0.76% | +15.40% | +21.77% | +2.89% | 0.77 | 1.25 | 1.77 | Compare |
| Nippon India Pharma Fund | 2/9 | 9,166 | 0.99% | +9.05% | +18.56% | −2.50% | 0.88 | 0.97 | 1.39 | Compare |
| Bandhan Transportation and Logistics Fund | 3/9 | 771 | 1.07% | −1.82% | +17.11% | +1.71% | 0.84 | 0.69 | 0.97 | Compare |
| Nippon India Power & Infra Fund | 4/9 | 7,867 | 1.11% | −2.17% | +16.41% | +2.80% | 0.97 | 0.59 | 0.78 | Compare |
| Invesco India Financial Services Fund | 5/9 | 1,789 | 0.96% | −2.22% | +15.03% | +5.53% | 0.93 | 0.55 | 0.77 | Compare |
| Invesco India Pharma and Healthcare Fund | -- | 436 | 3.30% | -- | -- | -- | -- | -- | -- |
AUM is each fund's size at the end of its last reported month, from its own portfolio file. We calculate the risk ratios from daily NAVs over the last three years. The risk-free return is what NSE's overnight rate index earned over the same years. Alpha and beta compare each fund with its own benchmark's TRI. "--" means we have no figure: for alpha and beta, no daily series for that benchmark.
What each plan charges a year, in force from 01-10-2026
| Plan | Base expense ratio | Brokerage | Transaction costs | Levies and GST | Total expense ratio | Sectoral median | Cost rank (1 = cheapest) |
|---|---|---|---|---|---|---|---|
| Direct | 0.50% | 0.86% | 0.05% | 1.89% | 3.30% | 1.07% | 20/20 |
| Regular | 2.10% | 0.86% | 0.05% | 2.18% | 5.19% | 2.51% | 20/20 |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, the cost of executing trades, and statutory levies with GST. From AMFI's expense ratio file. Cost rank: where this plan comes when the Sectoral funds' plans of the same type are sorted from the lowest total expense ratio to the highest.
Asset allocation as on 30-09-2026
87.0%Equity
| Asset | Fund | Category |
|---|---|---|
| Equity | 87.0% | 95.6% |
| Cash and others | 13.0% | 3.7% |
| Market cap | Fund | Category |
|---|---|---|
| Large Cap | 29.8% | 44.1% |
| Mid Cap | 16.4% | 21.8% |
| Small Cap | 32.8% | 26.9% |
| Not on AMFI's list | 8.0% | 2.3% |
Share of the whole fund. Category: the average of the Sectoral funds that hold stocks. Groups follow AMFI's latest list, as SEBI defines them: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Sector allocation of the fund's stocks as on 30-09-2026
Healthcare Services45.6%
Pharmaceuticals & Biotechnology41.4%
As on 30-09-2026 · 13 holdings · from the fund house's monthly portfolio
| Holdings | Sector | Weight% | Holdings trend | 1M change |
|---|---|---|---|---|
| Max Healthcare Institute Limited | Healthcare Services | 9.58% | ||
| Sun Pharmaceutical Industries Limited | Pharmaceuticals & Biotechnology | 8.99% | ||
| Sai Life Sciences Limited | Pharmaceuticals & Biotechnology | 8.63% | ||
| Apollo Hospitals Enterprise Limited | Healthcare Services | 8.03% | ||
| Manipal Health Enterprises Ltd | Healthcare Services | 7.98% | ||
| Divi's Laboratories Limited | Pharmaceuticals & Biotechnology | 7.85% | ||
| Global Health Limited | Healthcare Services | 7.00% | ||
| Dr Agarwals Health Care Limited | Healthcare Services | 6.32% | ||
| Corona Remedies Limited | Pharmaceuticals & Biotechnology | 6.13% | ||
| Torrent Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 4.93% | ||
| Glenmark Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 4.86% | ||
| Krishna Institute Of Medical Sciences Limited | Healthcare Services | 4.72% | ||
| Aster DM Quality Care Limited | Healthcare Services | 1.99% |
September 2026 is the first month we hold for this fund, so there is no earlier month to compare it with.
What Invesco India Pharma and Healthcare Fund bought and sold
Funds with the most similar portfolios, across every fund house and category
| Fund | Overlap | Holdings in common | |
|---|---|---|---|
| Mirae Asset Healthcare FundThematic · Mirae Asset | 43.1% | 9 | Compare |
| Mirae Asset Nifty 500 Healthcare ETFETF · Mirae Asset | 41.1% | 10 | Compare |
| DSP Nifty Healthcare Index FundIndex · DSP | 40.2% | 7 | Compare |
| Axis NIFTY Healthcare ETFETF · Axis | 40.2% | 7 | Compare |
| Aditya Birla Sun Life Nifty Healthcare ETFETF · Aditya Birla Sun Life | 40.2% | 7 | Compare |
| ICICI Prudential Nifty Healthcare ETFETF · ICICI Prudential | 40.2% | 7 | Compare |
| DSP Nifty Healthcare ETFETF · DSP | 40.2% | 7 | Compare |
| LIC MF Healthcare FundThematic · LIC | 40.2% | 9 | Compare |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 40% means 40% of each fund's money sits in positions the other also holds. From each fund's latest monthly portfolio, matched by ISIN. Cash and hedged positions are left out. Funds that overlap under 10% are not listed. A high overlap does not make two funds the same: their costs, lock-in and category can differ.
Fund facts from the scheme summary document, as on 16-10-2026
Rules in force from 23-07-2024 (Finance Act 2024). Tax depends on your own income; this is general information, not tax advice.
| Plan | Option | NAV | As on |
|---|---|---|---|
| direct | Growth | ₹9.66 | 30-10-2026 |
| direct | IDCW | ₹9.66 | 30-10-2026 |
| regular | Growth | ₹9.63 | 30-10-2026 |
| regular | IDCW | ₹9.63 | 30-10-2026 |
Invesco India Pharma and Healthcare Fund is a mutual fund from Invesco Mutual Fund. Its category is Sectoral. It was launched on 01-09-2026. Its benchmark is BSE Healthcare TRI. At the end of September 2026 it held 13 securities.
Aditya Khemani
Fund manager of Invesco India Pharma and Healthcare Fund
See all funds of Invesco Mutual Fund
AUM moves with money invested or taken out, and with the value of what the fund holds.
Returns, risk, costs and the stocks they share, side by side
The Direct plan NAV is ₹9.66. The Regular plan NAV is ₹9.63, as on 30-10-2026.
The Direct plan charges 3.30% a year. The Regular plan charges 5.19% a year. This is the figure the fund house reported to AMFI, in force from 01-10-2026.
Invesco India Pharma and Healthcare Fund managed ₹435.52 Cr on 30-09-2026, as its fund house reported in its monthly portfolio.
At the end of September 2026 the largest holdings were MAXHEALTH (9.58%), SUNPHARMA (8.99%), SAILIFE (8.63%), APOLLOHOSP (8.03%), MANIPALHOS (7.98%). The fund held 13 securities in all.
Through Invesco Mutual Fund's website or app, a mutual fund distributor, or an investment platform. Choose the Direct plan to pay no distributor commission, or the Regular plan to invest through a distributor. You can invest once or through a monthly SIP.
Aditya Khemani.
Exit load of 0.50%, if redeemed within 3 months.
No. You can redeem your units on any business day. An exit load may still apply.
Sources: NAV and expense ratio from AMFI. Holdings from the fund house's monthly portfolio statement. Fund facts from its scheme summary document, as on 16-10-2026.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.
Track Invesco India Pharma and Healthcare Fund in WealthGamma
Add this fund once. WealthGamma updates its value every day and shows it next to your stocks, gold, deposits and loans.
PAN not required · No broker linking · No OTPs